var data={"title":"Norethindrone: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Norethindrone: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6667?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=norethindrone-drug-information\" class=\"drug drug_general\">see &quot;Norethindrone: Drug information&quot;</a> and <a href=\"topic.htm?path=norethindrone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Norethindrone: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202477\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Aygestin;</li>\n      <li>Camila;</li>\n      <li>Deblitane;</li>\n      <li>Errin;</li>\n      <li>Heather;</li>\n      <li>Jencycla;</li>\n      <li>Jolivette;</li>\n      <li>Lyza;</li>\n      <li>Nor-QD [DSC];</li>\n      <li>Nora-BE;</li>\n      <li>Norlyda;</li>\n      <li>Norlyroc;</li>\n      <li>Ortho Micronor;</li>\n      <li>Sharobel</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202478\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Jencycla;</li>\n      <li>Micronor;</li>\n      <li>Movisse;</li>\n      <li>Norlutate</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060617\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Contraceptive, Oral</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Contraceptive, Progestin Only</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Progestin</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060611\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=norethindrone-drug-information\" class=\"drug drug_general\">see &quot;Norethindrone: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Abnormal uterine bleeding and amenorrhea (secondary):</b> Postmenarche females: Limited data in postmenarche children: Norethindrone acetate: Oral: 2.5 to 10 mg once daily for 5 to 12 days each month; most pediatric experts suggest 5 mg once daily for 12 days per month (Kliegman 2011; Kliegman 2016). Secretory transformation of the endometrium will occur when adequately primed with endogenous or exogenous estrogen. Withdrawal bleeding may be expected within 3 to 7 days after discontinuing norethindrone acetate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Contraception: </b>Postmenarche adolescent females: Norethindrone: Oral: 0.35 mg once daily every day (no missed days)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial dose: Start on first day of menstrual period or the day after a miscarriage or abortion. If switching from a combined oral contraceptive, begin the day after finishing the last active combined tablet.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Missed dose: Take as soon as remembered. A back-up method of contraception should be used for 48 hours if dose is taken &ge;3 hours late.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Additional contraception dosing considerations (CDC 2016a):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initiation of therapy: May be started at any time in the menstrual cycle once it is determined that the female is not pregnant. Back-up contraception is not needed if started within 5 days of onset of menstruation. If started &gt;5 days after the onset of menstruation or at any time in a female experiencing amenorrhea (not postpartum), back up contraception should be used for 2 days.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Switching from a different contraceptive to a progestin-only contraceptive: May be started at any time if it is determined that the female is not pregnant. Unless the female abstains from sexual intercourse, a back-up method of contraception is needed if it has been &gt;5 days since menstrual bleeding has begun. When an additional method of contraception is needed, consider continuing the woman&rsquo;s previous method for 2 days after starting the progestin-only contraceptive.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Switching from an IUD to a progestin-only contraceptive: Continue the IUD for at least 2 days after the progestin-only contraceptive is started or advise the female to abstain from sexual intercourse or use a barrier contraceptive for 7 days before removing the IUD. Alternately, an emergency contraceptive may be used at the time of IUD removal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endometriosis:</b> Postmenarche females &ge;10 years: Limited data in children 10 to 12 years (Kaser 2012): Norethindrone acetate: Oral: 5 mg once daily for 14 days; increase at increments of 2.5 mg/day every 2 weeks to reach target maintenance of 15 mg/day; continue for 6 to 9 months or until breakthrough bleeding demands temporary termination</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Abnormal uterine bleeding and amenorrhea:</b> Females: Oral: Norethindrone acetate: 2.5 to 10 mg/day for 5 to 10 days. Secretory transformation of the endometrium will occur when adequately primed with endogenous or exogenous estrogen. Withdrawal bleeding may be expected within 3 to 7 days after discontinuing norethindrone acetate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Contraception:</b> Females: Oral: Norethindrone: 0.35 mg every day (no missed days)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial dose: Start on first day of menstrual period or the day after a miscarriage or abortion. If switching from a combined oral contraceptive, begin the day after finishing the last active combined tablet.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Missed dose: Take as soon as remembered. A back-up method of contraception should be used for 48 hours if dose is taken &ge;3 hours late.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Additional contraception dosing considerations (CDC 2016a):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initiation of therapy: May be started at any time in the menstrual cycle once it is determined that the woman is not pregnant. Back-up contraception is not needed if started within 5 days of onset of menstruation. If started &gt;5 days after the onset of menstruation or at any time in a woman experiencing amenorrhea (not postpartum), back-up contraception should be used for 2 days.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Switching from a different contraceptive to a progestin-only contraceptive: May be started at any time if it is determined that the woman is not pregnant. Unless the woman abstains from sexual intercourse, a back-up method of contraception is needed if it has been &gt;5 days since menstrual bleeding has begun. When an additional method of contraception is needed, consider continuing the woman&rsquo;s previous method for 2 days after starting the progestin-only contraceptive.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Switching from an IUD to a progestin-only contraceptive: Continue the IUD for at least 2 days after the progestin-only contraceptive is started or advise the woman to abstain from sexual intercourse or use a barrier contraceptive for 7 days before removing the IUD. Alternately, an emergency contraceptive may be used at the time of IUD removal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endometriosis:</b> Females: Oral: Norethindrone acetate: 5 mg/day for 14 days; increase at increments of 2.5 mg/day every 2 weeks to reach 15 mg/day; continue for 6 to 9 months or until breakthrough bleeding demands temporary termination</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, use is contraindicated in patients with hepatic tumors or impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202457\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Camila: 0.35 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Deblitane: 0.35 mg [contains fd&amp;c blue #2 aluminum lake, fd&amp;c red #40 aluminum lake, fd&amp;c yellow #10 aluminum lake, soybean lecithin]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Errin: 0.35 mg [contains corn starch, fd&amp;c yellow #10 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Heather: 0.35 mg [contains fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Jencycla: 0.35 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Jolivette: 0.35 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lyza: 0.35 mg [contains corn starch, fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nor-QD: 0.35 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nora-BE: 0.35 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Norlyda: 0.35 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Norlyroc: 0.35 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ortho Micronor: 0.35 mg [contains corn starch, fd&amp;c yellow #10 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sharobel: 0.35 mg [contains fd&amp;c blue #1 aluminum lake, fd&amp;c yellow #6 aluminum lake, soybean lecithin]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.35 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as acetate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aygestin: 5 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202444\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060621\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer at the same time each day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">When used for the prevention of pregnancy, a back-up method of contraception should be used for 48 hours if dose is missed or taken &ge;3 hours late. If vomiting or severe diarrhea occur within 3 hours of taking a dose, take another dose as soon as possible, then continue taking one dose daily and use a backup method of contraception (or avoid sexual intercourse) until 2 days after vomiting or diarrhea have resolved. Emergency contraception should be considered in the event of unprotected intercourse (CDC 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49322208\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6202484\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at controlled room temperature.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060620\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Norethindrone: Prevention of pregnancy (FDA approved in postmenarche pediatric and adult females); <b>Note:</b> Not indicated for emergency contraception.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Norethindrone acetate: Treatment of amenorrhea, endometriosis, and abnormal uterine bleeding (FDA approved in postmenarche pediatric and adult females) <b></b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202514\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Micronor may be confused with miconazole, Micronase</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202513\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Cerebral embolism, cerebral thrombosis, deep vein thrombosis, edema, pulmonary embolism, retinal thrombosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Depression, dizziness, fatigue, headache, insomnia, migraine, emotional lability, nervousness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Acne vulgaris, alopecia, chloasma, pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Amenorrhea, hirsutism, hypermenorrhea, menstrual disease, weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Breakthrough bleeding, breast hypertrophy, breast tenderness, cervical erosion, change in cervical secretions, decreased lactation, genital discharge, mastalgia, spotting, vaginal hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylaxis, hypersensitivity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Cholestatic jaundice, hepatitis, abnormal hepatic function tests </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Arm pain, leg pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Optic neuritis (with or without vision loss)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202461\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to norethindrone or any component of the formulation; hepatic impairment or disease; breast cancer (known, suspected, or history of); undiagnosed abnormal genital bleeding; pregnancy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Norethindrone: Additional contraindications: Benign or malignant liver tumors</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Norethindrone acetate:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Additional contraindications: DVT or PE (current or history of); active or recent history of arterial thromboembolic disease (eg, stroke, MI); as a diagnostic test for pregnancy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Additional contraindications in Canadian labeling: Estrogen or progestin dependent malignant tumor; partial or complete vision loss due to ophthalmic vascular disease; missed abortion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202448\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding: Irregular menstrual bleeding patterns are common with progestin-only contraceptives; nonpharmacologic causes of abnormal bleeding should be ruled out.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Breast cancer: The use of combination hormonal contraceptives has been associated with a slight increase in the frequency of breast cancer, however studies are not consistent. Data is insufficient to determine if progestin-only contraceptives also increase this risk. Norethindrone and norethindrone acetate are contraindicated in women with breast cancer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Delayed follicular atresia/ovarian cysts: If follicular development occurs following use for contraception, follicles may grow and enlarge beyond the size attained in a normal cycle. May be asymptomatic or can be associated with mild abdominal pain; surgical intervention is rarely required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ectopic pregnancy: The possibility of ectopic pregnancy following use of a progestin-only contraceptive should be considered in patients with lower abdominal pain.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lipid effects: May have adverse effects on lipid metabolism; use caution in women with hyperlipidemias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Visual abnormalities: Norethindrone acetate: Discontinue if migraine, loss of vision, proptosis, diplopia, or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Norethindrone acetate: Risk factors for cardiovascular disorders include diabetes mellitus, hypercholesterolemia, hypertension, SLE, obesity, tobacco use, and/or history of venous thromboembolism (VTE). Risk factors should be managed appropriately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Depression: Norethindrone acetate: Use with caution in patients with depression. Progestin only contraceptive tablets may be used in women with depression (Curtis 2016b).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: May have adverse effects on glucose tolerance; use caution in women with diabetes. Progestin only contraceptive tablets may be used in women with diabetes (Curtis 2016b).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diseases exacerbated by fluid retention: Norethindrone acetate: Use with caution in patients with diseases which may be exacerbated by fluid retention, including asthma, epilepsy, or cardiac or renal dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic adenomas: Extremely rare hepatic adenomas and focal nodular hyperplasia resulting in fatal intra-abdominal hemorrhage have been reported in association with long-term combination oral contraceptive use. Data is insufficient to determine if progestin-only contraceptives also increase this risk. Use as a contraceptive is contraindicated in women with hepatic tumors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Migraine: Use with caution in patients with a history of migraine. Progestin-only contraceptive tablets may be used in women with a history of headache or migraine; new headaches or changes in headaches should be evaluated (Curtis 2016b).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Concurrent drug therapy issues:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Not for use prior to menarche.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Smokers: Progestin-only contraceptives may be used in women who smoke (Curtis 2016b). Because of an increased risk of cardiovascular disease, women using oral contraceptives should be strongly advised not to smoke.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Norethindrone: Progestin-only contraceptives contain less progestin than contained in estrogen/progestin&ndash;combined contraceptives. Risks associated with estrogen/progestin contraceptives should be considered for progestin-only products.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; HIV infection protection: Progestin-only contraceptives do not protect against HIV infection or other sexually transmitted diseases.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Laboratory changes: The use of estrogens and/or progestins may change the results of some laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). The dose, route, and the specific estrogen/progestin influence these changes. In addition, personal risk factors (eg, cardiovascular disease, smoking, diabetes, age) also contribute to adverse events; use of specific products may be contraindicated in women with certain risk factors.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202506\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202452\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12652&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acitretin: May diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. Management: Given the potential for progestin-only preparations to fail to prevent pregnancy during acitretin therapy, such products should not be relied upon. Alternative, nonhormonal forms of contraception must be employed during acitretin therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Progestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.  Management: Carefully weigh the prospective benefits of progestins against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May decrease the serum concentration of Progestins (Contraceptive). Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Artemether: May decrease the serum concentration of Progestins (Contraceptive). Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: May increase the serum concentration of Progestins (Contraceptive). However, atazanavir may lead to decreased ethinyl estradiol concentrations and decreased effectiveness of oral contraceptive products. Management: Consider an alternative or additional method of contraception, particularly with combined estrogen/progestin products. Depot medroxyprogesterone acetate may be used without a need for additional contraception.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bexarotene (Systemic): May decrease the serum concentration of Progestins (Contraceptive). Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (including at least one nonhormonal form).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the serum concentration of Progestins (Contraceptive). Management: Administer oral progestin-containing contraceptives at least 1 to 4 hours prior to or 4 to 6 hours after administration of a bile acid sequestrant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: May increase the serum concentration of Progestins (Contraceptive). This has been seen specifically with drospirenone. Boceprevir may increase the serum concentration of Progestins (Contraceptive). This has been seen specifically with norethindrone. Management: Patients receiving boceprevir, ribavirin, and peginterferon alfa should use two reliable forms of contraception.  Norethindrone/ethinyl estradiol may be used for one of these when norethindrone dose is at least 1 mg/day. Avoid drospirenone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of Progestins (Contraceptive). Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May decrease the serum concentration of Progestins (Contraceptive). Management: Females of childbearing potential should use an alternative, non-hormonal contraceptive during brigatinib therapy and for at least 4 months after the final brigatinib dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">C1 inhibitors: Progestins may enhance the thrombogenic effect of C1 inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carfilzomib: May enhance the thrombogenic effect of Progestins (Contraceptive). Management: Consider alternative, non-hormonal methods of contraception in patients requiring therapy with carfilzomib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloBAZam: May decrease the serum concentration of Progestins (Contraceptive).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of Progestins (Contraceptive). Management: Consider an alternative, non-hormone-based contraceptive in patients receiving cobicistat-containing products. Drospirenone is specifically contraindicated with atazanavir and cobicistat.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colesevelam: May decrease the serum concentration of Norethindrone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of Progestins (Contraceptive). Management: Females of reproductive potential should use an alternative, highly effective, non-hormonal means of contraception during and at least 2 weeks (dabrafenib alone) or 4 months (dabrafenib + trametinib) after discontinuation of dabrafenib treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May decrease the serum concentration of Norethindrone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May decrease the serum concentration of Progestins (Contraceptive). Management: Use an alternative or additional method of contraception due to possibly decreased contraceptive effectiveness. Injected depot medroxyprogesterone acetate does not appear to participate in this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eslicarbazepine: May decrease the serum concentration of Progestins (Contraceptive). Management: Alternative, non-hormonal means of birth control should be considered for women of child-bearing potential.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Exenatide: May decrease the serum concentration of Progestins (Oral Contraceptive). Management: Administer oral contraceptives at least one hour prior to exenatide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Felbamate: May decrease the serum concentration of Progestins (Contraceptive). Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal method of contraception is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: Progestins (Contraceptive) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosamprenavir: Progestins (Contraceptive) may decrease serum concentrations of the active metabolite(s) of Fosamprenavir. Fosamprenavir may decrease the serum concentration of Progestins (Contraceptive).  Management: Consider using an alternative or additional means of contraception.  Injected depot medroxyprogesterone acetate may be used without a need for additional contraception.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May decrease the serum concentration of Progestins (Contraceptive). The active metabolite aprepitant is likely responsible for this effect. Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Griseofulvin: May diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Progestogenic Properties) (eg, Bloodroot, Yucca): May enhance the adverse/toxic effect of Progestins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ixazomib: May decrease the serum concentration of Progestins (Contraceptive). More specifically, use of ixazomib with dexamethasone may decrease the serum concentrations of contraceptive progestins. Management: Patients of childbearing potential should use a nonhormonal barrier contraceptive during and 90 days following ixazomib treatment.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LamoTRIgine: May decrease the serum concentration of Progestins (Contraceptive).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lesinurad: May decrease the serum concentration of Progestins (Contraceptive). Management: Use of an additional, nonhormonal contraceptive is recommended in patients being treated with lesinurad who desire effective contraception.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lixisenatide: May decrease the serum concentration of Progestins (Contraceptive). Management: Administer oral contraceptives 1 hour before or at least 11 hours after administration of lixisenatide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lopinavir: May decrease the serum concentration of Progestins (Contraceptive). Lopinavir may increase the serum concentration of Progestins (Contraceptive). Management: Consider using an alternative or additional means of contraception.  Injected depot medroxyprogesterone acetate and etonogestrel implants may be used without a need for additional contraception.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of Progestins (Contraceptive). Management: Do not rely on hormone-based contraceptives with concurrent use of lumacaftor/ivacaftor; an alternative, non-hormonal, method of contraception should be used if this combination is required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metreleptin: May decrease the serum concentration of Progestins (Contraceptive). Metreleptin may increase the serum concentration of Progestins (Contraceptive).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May diminish the therapeutic effect of Progestins (Contraceptive). MiFEPRIStone may increase the serum concentration of Progestins (Contraceptive). Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: May decrease the serum concentration of Progestins (Contraceptive). Management: Use of an additional or alternative (nonhormonal) method of contraception should be considered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nelfinavir: May decrease the serum concentration of Progestins (Contraceptive). Management: Use an alternative or additional method of contraception due to possibly decreased contraceptive effectiveness. Injected depot medroxyprogesterone acetate does not appear to participate in this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nevirapine: May decrease the serum concentration of Progestins (Contraceptive). Management: Instruct patients receiving nevirapine to use an alternative or additional nonhormonal contraceptive. Nevirapine product labeling however suggests that depo-medroxyprogesterone acetate may be used as a sole method of contraception.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OXcarbazepine: May decrease the serum concentration of Progestins (Contraceptive). Management: Contraceptive failure is possible.  Use of an additional or alternative, nonhormonal method of contraception is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May decrease the serum concentration of Progestins (Contraceptive). Management: Patients should use an alternative, nonhormonal-based form of contraception both during the concurrent use of perampanel and for 1 month after discontinuing perampanel.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May diminish the therapeutic effect of Progestins (Contraceptive). Management: The combination of hormonal contraceptives with pitolisant should be avoided, and an alternate means of contraception should be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pomalidomide: Progestins may enhance the thrombogenic effect of Pomalidomide.  Management: Canadian pomalidomide labeling recommends caution with use of hormone replacement therapy and states that hormonal contraceptives are not recommended. US pomalidomide labeling does not contain these specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primidone: May diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prucalopride: May decrease the serum concentration of Progestins (Contraceptive).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Retinoic Acid Derivatives: May diminish the therapeutic effect of Progestins (Contraceptive). Retinoic Acid Derivatives may decrease the serum concentration of Progestins (Contraceptive). Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives.  Particularly, microdosed progesterone-only preparations may be inadequately effective.<b> Exceptions: </b>Adapalene; Bexarotene (Topical); Tretinoin (Topical).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of Progestins (Contraceptive). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May decrease the serum concentration of Norethindrone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saquinavir: May decrease the serum concentration of Progestins (Contraceptive). Management: Use an alternative or additional method of contraception due to possibly decreased contraceptive effectiveness. Injected depot medroxyprogesterone acetate does not appear to participate in this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selegiline: Progestins (Contraceptive) may increase the serum concentration of Selegiline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. Management: Consider using a product other than St John's wort.  Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sugammadex: May decrease the serum concentration of Progestins (Contraceptive). Management: Patients receiving any hormonal contraceptive (oral or non-oral) should use an additional, nonhormonal contraceptive method during and for 7 days following sugammadex treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May decrease the serum concentration of Progestins (Contraceptive). Management: Two different nonhormonal forms of contraception are required for women of childbearing potential taking telaprevir.  Hormonal contraceptives may be less effective during concurrent telaprevir and for up to 2 weeks after telaprevir discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: Progestins (Contraceptive) may enhance the thrombogenic effect of Thalidomide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May increase the serum concentration of Progestins (Contraceptive). Management: Use an alternative or additional method of contraception due to possibly decreased contraceptive effectiveness. Injected depot medroxyprogesterone acetate does not appear to participate in this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: May decrease the serum concentration of Progestins (Contraceptive). Management: Caution patients that this combination may be associated with reduced contraceptive effectiveness.  Consider adding an additional (non-hormonal) contraceptive method.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tranexamic Acid: Progestins (Contraceptive) may enhance the thrombogenic effect of Tranexamic Acid. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ulipristal: Progestins may diminish the therapeutic effect of Ulipristal. Ulipristal may diminish the therapeutic effect of Progestins.  Management: Ulipristal for uterine fibroids (Canadian indication): avoid progestins within 12 days of stopping ulipristal; as emergency contraceptive (U.S. indication): avoid progestins within 5 days of stopping ulipristal.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Progestins (Contraceptive) may diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.  Management: When possible, concomitant hormonal contraceptives and coumarin derivatives should be avoided in order to eliminate the risk of thromboembolic disorders.  Consider using an alternative, nonhormonal contraceptive.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May increase the serum concentration of Progestins (Contraceptive). Progestins (Contraceptive) may increase the serum concentration of Voriconazole.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202453\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (norethindrone acetate) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5120967\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Use is contraindicated during pregnancy. First trimester exposure of progestins may cause genital abnormalities including hypospadias in male infants and mild virilization of external female genitalia. Changes in external genitalia have been reported in female infants exposed to norethindrone acetate (Fine 1963). Significant adverse events related to growth and development have not been observed following use of oral progestins in contraceptive doses (limited studies).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Norethindrone:</b> Progestin-only contraceptives may be started immediately postpartum (Curtis 2016a; Curtis 2016b). A rapid return to fertility occurs when progestin-only contraceptives are discontinued.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Norethindrone acetate:</b> The contraceptive dose of norethindrone acetate is not known. Barrier contraception is recommended to prevent unintended pregnancy (eg, when treating endometriosis) (Kaser 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50772790\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Norethindrone: Contraception: Assessment of pregnancy status (prior to therapy); weight (optional; BMI at baseline may be helpful to monitor changes during therapy); assess potential health status changes at routine visits (Curtis 2016a)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Norethindrone acetate: Monitor patient for vision changes; signs or symptoms of depression; glycemic control in patients with diabetes; lipid profiles in patients being treated for hyperlipidemias</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Regardless of indication, adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding. Pathologist should be informed of therapy when submitting endometrial tissue for histologic evaluation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202447\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Once absorbed, systemic disposition of norethindrone acetate (NETA) and norethindrone (NET) is the same.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NET is used in preparations for progestin-only contraception. NET suppresses ovulation, thickens cervical mucus (which inhibits sperm penetration), alters follicle-stimulating hormone (FSH) and luteinizing hormone (LH) concentrations, slows the movement of ovum through the fallopian tubes, and alters the endometrium.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestogens, such as NETA in the doses used for abnormal uterine bleeding, amenorrhea, and endometriosis, lead to atrophy of the endometrial tissue. They may also suppress new growth and implantation. Pain associated with endometriosis is decreased. When treating endometriosis, NETA may be used in combination with gonadotropin-releasing hormone agonists to decrease side effects from hypoestrogenism (ASRM 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202460\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Rapidly absorbed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 4 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 61% to albumin; 36% to sex hormone-binding globulin (SHBG); SHBG capacity affected by plasma ethinyl estradiol levels (Orme 1983)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Oral: Norethindrone acetate is deacetylated to norethindrone; norethindrone undergoes hepatic reduction and conjugation; orally administered norethindrone is subject to first-pass effect (Orme 1983). In addition to forming glucuronide and sulfide conjugates, norethindrone is also metabolized to ethinyl estradiol  (Kuhnz 1997; Orme 1983).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: 64% (Orme 1983)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~8 to 9 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: ~2 hours (varies by dose and use of concomitant estrogen (Orme 1983)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (&gt;50% as metabolites); feces (20% to 40% as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202462\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Aygestin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (50): $261.24</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Camila Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.35 mg (28): $36.91</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Deblitane Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.35 mg (28): $36.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Errin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.35 mg (28): $36.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Heather Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.35 mg (28): $36.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Jencycla Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.35 mg (28): $36.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Jolivette Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.35 mg (28): $36.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Lyza Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.35 mg (28): $36.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Nora-BE Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.35 mg (28): $36.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Norethindrone Acetate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (50): $132.43</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Norethindrone Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.35 mg (28): $36.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Norlyda Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.35 mg (28): $67.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Norlyroc Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.35 mg (28): $110.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ortho Micronor Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.35 mg (28): $65.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Sharobel Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.35 mg (28): $36.92</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202465\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aminor (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Ethinor (BD);</li>\n      <li>Menogia (BD);</li>\n      <li>Menoral-S (LK);</li>\n      <li>Micro-Novom (ZA);</li>\n      <li>Micronor (AE, BF, BH, BJ, BR, CI, CY, EG, ET, GB, GH, GM, GN, IE, IL, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Micronovum (AT, CH, DE, ZA);</li>\n      <li>Mini-PE (DK);</li>\n      <li>Nor Prymolyut (UA);</li>\n      <li>Norcolut (BB, BM, BS, BZ, EE, GY, HK, HU, JM, MY, PR, SR, TT, VN);</li>\n      <li>Norcutin (MY, SG);</li>\n      <li>Norestin (BR);</li>\n      <li>Noretone (ZW);</li>\n      <li>Norgest (LK);</li>\n      <li>Noriday (AE, BF, BH, BJ, CI, ET, GB, GH, GM, GN, IE, KE, LR, MA, ML, MR, MU, MW, MY, NE, NG, NZ, QA, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Noriday 28 (AU);</li>\n      <li>Norkolut (UA);</li>\n      <li>Norlut-N (LK);</li>\n      <li>Norluten (FR);</li>\n      <li>Ortho-Novum (MX);</li>\n      <li>Primolut (EG, PK);</li>\n      <li>Primolut N (AE, BB, BD, BF, BH, BJ, BM, BS, BZ, CH, CI, CL, CY, DE, EG, ET, FI, GB, GH, GM, GN, GY, ID, IE, IL, IQ, IR, IS, JM, JO, JP, KE, KR, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, NE, NG, NL, NO, OM, PH, PK, PL, PR, QA, SA, SC, SD, SG, SL, SN, SR, SY, TH, TN, TR, TT, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Primolut Nor (AR, BE, BG, CZ, EC, GR, IT, LU, PT, PY, RU, SE, SI, UY, VN);</li>\n      <li>Primolut-N (KR, LK);</li>\n      <li>Primolut-Nor (ES);</li>\n      <li>Primolutin (DE);</li>\n      <li>Regamen (ID);</li>\n      <li>Renorcyl (BD);</li>\n      <li>Rontril (BD);</li>\n      <li>Shiton (TW);</li>\n      <li>Steron (TH);</li>\n      <li>Styptin 5 (IN);</li>\n      <li>Utovlan (GB)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists, &ldquo;ACOG Committee Opinion. Number 310, April 2005. Endometriosis in Adolescents,&rdquo; <i>Obstet Gynecol</i>, 2005, 105(4):921-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/15802438/pubmed\" target=\"_blank\" id=\"15802438\">15802438</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins-Gynecology, &ldquo;ACOG Practice Bulletin. No. 73: Use of Hormonal Contraception in Women With Coexisting Medical Conditions,&rdquo; <i>Obstet Gynecol</i>, 2006, 107(6):1453-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/16738183/pubmed\" target=\"_blank\" id=\"16738183\">16738183</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aygestin (norethindrone acetate) [prescribing information]. North Wales, PA: Teva Women's Health; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Camila (norethindrone) [prescribing information]. North Wales, PA: Teva Pharmaceuticals; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). U.S. Medical Eligibility Criteria for Contraceptive Use, 2010. <i>MMWR Recomm Rep</i>. 2010;59(RR-4):1-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/20559203/pubmed\" target=\"_blank\" id=\"20559203\">20559203</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). U.S. Selected Practice Recommendations for Contraceptive Use, 2013: adapted from the World Health Organization selected practice recommendations for contraceptive use, 2nd edition. <i>MMWR Recomm Rep</i>. 2013 Jun;62(RR-05):1-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/23784109/pubmed\" target=\"_blank\" id=\"23784109\">23784109</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. <i>MMWR Recomm Rep</i>. 2016a;65(4):1-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/27467319/pubmed\" target=\"_blank\" id=\"27467319\">27467319</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. <i>MMWR Recomm Rep</i>. 2016b;65(3):1-103.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/27467196/pubmed\" target=\"_blank\" id=\"27467196\">27467196</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Deblitane (norethindrone) [prescribing information]. Memphis, TN: Northstar Rx; March 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Errin (norethindrone) [prescribing information]. Greenville, NC: Mayne Pharma; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobstein R, Polis CB. Progestin-only contraception: injectables and implants. <i>Best Pract Res Clin Obstet Gynaecol</i>. 2014;28(6):795-806.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/24996766/pubmed\" target=\"_blank\" id=\"24996766\">24996766</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jencycla (norethindrone) [prescribing information]. Baltimore, MD: Lupin Pharmaceuticals; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jencycla (norethindrone) [product monograph]. Boucherville, Quebec, Canada: Sandoz Canada Inc.; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jolivette (norethindrone) [prescribing information]. Corona, CA: Watson Pharma; August 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaser DJ, Missmer SA, Berry KF, Laufer MR. Use of norethindrone acetate alone for postoperative suppression of endometriosis symptoms. <i>J Pediatr Adolesc Gynecol</i>. 2012;25(2):105-108.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/22154396/pubmed\" target=\"_blank\" id=\"22154396\">22154396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kuhnz W, Heuner A, H&uuml;mpel M, Seifert W, Michaelis K. In vivo conversion of norethisterone and norethisterone acetate to ethinyl etradiol in postmenopausal women. <i>Contraception</i>. 1997;56(6):379-385.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/9494772/pubmed\" target=\"_blank\" id=\"9494772\">9494772</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lyza (norethindrone) [prescribing information]. Charleston, SC: Afaxys; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Norlyroc (norethindrone) [prescribing information]. North Brunswick, NJ: Ohm Laboratories Inc; February 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis: a committee opinion. <i>Fertil Steril</i>. 2014;101(4):927-935.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/24630080/pubmed\" target=\"_blank\" id=\"24630080\">24630080</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sharobel (norethindrone) [prescribing information]. Memphis, TN: Northstar Rx; March 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in the healthcare settings 2014. Available at: <a href=\"http://www.cdc.gov/niosh/docs/2014-138/pdfs/2014-138.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/docs/2014-138/pdfs/2014-138.pdf</a>. Updated September 2014. Accessed September 15, 2014.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12652 Version 175.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F202477\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F202478\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1060617\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1060611\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F202457\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F202444\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1060621\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49322208\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F6202484\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1060620\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F202514\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F202513\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F202461\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F202448\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F202506\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F202452\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F202453\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5120967\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F50772790\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F202447\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F202460\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F202462\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F202465\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12652|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=norethindrone-drug-information\" class=\"drug drug_general\">Norethindrone: Drug information</a></li><li><a href=\"topic.htm?path=norethindrone-patient-drug-information\" class=\"drug drug_patient\">Norethindrone: Patient drug information</a></li></ul></div></div>","javascript":null}